Coulter Partners Recruits CEO and Chief Business Officer for IMU Biosciences
December 6, 2024 – Life sciences recruiting specialist Coulter Partners has helped to recruit John Baker as chief executive officer and Jason Brown as chief business officer of biotechnology company IMU Biosciences. Founder and past CEO Adam Laing will assume the roles of president and chief scientific officer. “I am incredibly proud of what the IMU team has achieved to date,” said Dr. Laing. “We have built a powerful platform that has the potential to revolutionize precision medicine across a range of health conditions. I look forward to continuing to advance our scientific strategy and innovation, and to working closely with John and Jason to realize the full potential of our immune-powered approach.”
Dr. Baker joined IMU Biosciences from Abcam, a global life science tools company, where he most recently served as senior vice president, supply chain and manufacturing. He has been on the executive team at Abcam since 2016, during which time the business delivered exceptional growth, culminating in a successful acquisition for c. $5.7 billion and transition into Danaher Corporation in 2023. During his time at Abcam, Dr. Baker led global teams spanning business development, R&D, product, marketing, and supply chain & manufacturing.
Dr. Baker is trained as a veterinarian, undertaking both his undergraduate and clinical training in Cambridge. Following a spell in commercial animal practice, he moved to Oxford for a DPhil in clinical medicine, publishing on the molecular biology of the innate immune response. Dr. Baker spent six years with Bain and Company in London, where he was a leader in the company’s global healthcare practice. He has previously held non-executive director roles at both BrickBio and Somaserve.
“I am excited to join IMU Biosciences at a pivotal moment,” said Dr. Baker. “The company’s unique approach to immune profiling has huge potential, and I’m looking forward to guiding its continued growth and development. IMU’s proprietary technology platforms have the ability to meaningfully impact patient outcomes. Together with Adam, Jason, and the full IMU team, our mission is to advance our pipeline, forge strategic partnerships, and ultimately drive the delivery of life-changing therapies to patients.”
Dr. Brown joined IMU Biosciences from Evotec, an R&D biotech company, where he served as senior vice president of business development. He has a wealth of expertise in business development, scientific discovery partnerships, and drug discovery services. Previous roles include founding and leading Ubiquigent, a specialized drug discovery services company in the protein degradation field, where he secured key partnerships and drove scientific innovation. As IMU Biosciences’ first chief business officer, Dr. Brown will oversee the company’s business development and partnering efforts.
Related: Coulter Partners Recruits CEO for Tristel
IMU Biosciences is a biotechnology company pioneering systems-level immune profiling with AI to drive breakthroughs in precision medicine. The mission at IMU is to revolutionize this field by developing a groundbreaking, population-scale, systems-level understanding of the immune system. By leveraging its AI-powered immune profiling platform, based on a decade of research at King’s College London and the Francis Crick Institute, they are creating tools that offer unprecedented insights into disease and health, driving forward the future of precision medicine.
Serving Life Sciences Organizations
Coulter Partners is a board- and senior-level global executive search specialist focused exclusively on life sciences. The firm works closely with those at the cutting edge of innovation in the industry to understand their challenges. With an extensive global network and expertise gained over 25 years in the sector, Coulter Partners is a trusted leadership adviser in the pharmaceuticals, biotechnology, medical technology, diagnostics, health-tech, CRO, and services sectors.
Coulter Partners Recruits CEO for Nitinotes
Coulter Partners has assisted in the recruitment of Lloyd Diamond as the new CEO of Nitinotes Surgical in Caesarea, Israel. He succeeds Raz Bar-On, who will continue as general manager. “We are thrilled to welcome Lloyd to lead Nitinotes into its next chapter of innovation and growth,” said John Barr, chairman of the board. “Building upon the foundation established and the exceptional achievements attained, his extensive experience in medical technologies positions him as an outstanding leader to advance our future initiatives.”
“Lloyd’s appointment concludes a rigorous executive search process that MTIP initiated in collaboration with Coulter Partners,” Mr. Barr said. “We express our deep gratitude to Coulter Partners for their exceptional support. Their expert guidance was invaluable in identifying the ideal leader for Nitinotes. Their deep understanding of our specific needs and extensive network within the market were instrumental in delivering a successful outcome. Given the complexity of this role, finding the right candidate was a challenging task, but Coulter Partners’ professionalism and dedication ensured we found the perfect match.”
Coulter Partners also works closely with the global investor community, hiring for their own teams as well as building the boards and executive leadership teams of their portfolio companies. Coulter Partners’ team of 95 completes over 260 assignments a year working from 14 offices across the U.K., EMEA, the U.S., and APAC.
Bianca Coulter founded Coulter Partners in 2003 and has 25 years’ experience of board and C-level global search, building the leadership teams of early stage, mid-cap, and global multinationals in over 20 countries. Through appointing leadership, Ms. Coulter channels her judgment and expertise to impact patient benefit and assist those at the cutting edge of life science to achieve their goals.
Related: Coulter Partners Recruits CEO for ArcticZymes Technologies
Contributed by Scott A. Scanlon, Editor-in-Chief and Dale M. Zupsansky, Executive Editor – Hunt Scanlon Media
